TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
KYTX

Kyverna Therapeutics, Inc.

Healthcare · Biotechnology

5.70$ -3.1% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Kyverna Therapeutics, Inc. (KYTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.3% of the shares are freely tradable; institutional investors hold 74.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 74.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 7.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 58.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 18.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 62Mio.

Largest Shareholders

Institutions

Institutions KYTX
Name Stake (%) Shares Change (%) Date
GordonMD Global Investments LP 6.86 4,244,818 +0.0 06/30/2026
BlackRock Inc 5.07 3,134,807 +257.4 06/30/2026
Bain Capital Life Sciences Investors, LLC 4.67 2,885,000 -7.2 06/30/2026
AIGH Capital Management, LLC 4.52 2,795,797 +39.8 06/30/2026
Deerfield Management Co 3.23 2,000,000 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.07 1,897,451 +6.4 06/30/2026
T. Rowe Price Associates, Inc. 1.92 1,186,023 -23.7 06/30/2026

Funds

Funds KYTX
Name Stake (%) Shares Change (%) Date
MEDICAL BioHealth EUR Acc 2.85 1,763,368 +0.0 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.54 1,571,457 +12.0 09/30/2026
iShares Russell 2000 ETF 1.79 1,108,912 -1.1 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?